Cargando…
Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs
The pro-apoptotic BH3-only protein, BIK, is widely expressed and although many critical functions in developmental or stress-induced death have been ascribed to this protein, mice lacking Bik display no overt abnormalities. It has been postulated that Bik can serve as a tumour suppressor, on the bas...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366076/ https://www.ncbi.nlm.nih.gov/pubmed/22573037 http://dx.doi.org/10.1038/cddis.2012.42 |
_version_ | 1782234709099544576 |
---|---|
author | Happo, L Phipson, B Smyth, G K Strasser, A Scott, C L |
author_facet | Happo, L Phipson, B Smyth, G K Strasser, A Scott, C L |
author_sort | Happo, L |
collection | PubMed |
description | The pro-apoptotic BH3-only protein, BIK, is widely expressed and although many critical functions in developmental or stress-induced death have been ascribed to this protein, mice lacking Bik display no overt abnormalities. It has been postulated that Bik can serve as a tumour suppressor, on the basis that its deficiency and loss of apoptotic function have been reported in many human cancers, including lymphoid malignancies. Evasion of apoptosis is a major factor contributing to c-Myc-induced tumour development, but despite this, we found that Bik deficiency did not accelerate Eμ-Myc-induced lymphomagenesis. Co-operation between BIK and NOXA, another BH3-only protein, has been previously described, and was attributed to their complementary binding specificities to distinct subsets of pro-survival BCL-2 family proteins. Nevertheless, combined deficiency of Bik and Noxa did not alter the onset of Eμ-Myc transgene induced lymphoma development. Moreover, although p53-mediated induction of Bik has been reported, neither Eμ-Myc/Bik(−/−) nor Eμ-Myc/Bik(−/−)Noxa(−/−) lymphomas were more resistant than control Eμ-Myc lymphomas to killing by DNA damaging drugs, either in vitro or in vivo. These results suggest that Bik, even in combination with Noxa, is not a potent suppressor of c-Myc-driven tumourigenesis or critical for chemotherapeutic drug-induced killing of Myc-driven tumours. |
format | Online Article Text |
id | pubmed-3366076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-33660762012-06-04 Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs Happo, L Phipson, B Smyth, G K Strasser, A Scott, C L Cell Death Dis Original Article The pro-apoptotic BH3-only protein, BIK, is widely expressed and although many critical functions in developmental or stress-induced death have been ascribed to this protein, mice lacking Bik display no overt abnormalities. It has been postulated that Bik can serve as a tumour suppressor, on the basis that its deficiency and loss of apoptotic function have been reported in many human cancers, including lymphoid malignancies. Evasion of apoptosis is a major factor contributing to c-Myc-induced tumour development, but despite this, we found that Bik deficiency did not accelerate Eμ-Myc-induced lymphomagenesis. Co-operation between BIK and NOXA, another BH3-only protein, has been previously described, and was attributed to their complementary binding specificities to distinct subsets of pro-survival BCL-2 family proteins. Nevertheless, combined deficiency of Bik and Noxa did not alter the onset of Eμ-Myc transgene induced lymphoma development. Moreover, although p53-mediated induction of Bik has been reported, neither Eμ-Myc/Bik(−/−) nor Eμ-Myc/Bik(−/−)Noxa(−/−) lymphomas were more resistant than control Eμ-Myc lymphomas to killing by DNA damaging drugs, either in vitro or in vivo. These results suggest that Bik, even in combination with Noxa, is not a potent suppressor of c-Myc-driven tumourigenesis or critical for chemotherapeutic drug-induced killing of Myc-driven tumours. Nature Publishing Group 2012-05 2012-05-10 /pmc/articles/PMC3366076/ /pubmed/22573037 http://dx.doi.org/10.1038/cddis.2012.42 Text en Copyright © 2012 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Original Article Happo, L Phipson, B Smyth, G K Strasser, A Scott, C L Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs |
title | Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs |
title_full | Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs |
title_fullStr | Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs |
title_full_unstemmed | Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs |
title_short | Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs |
title_sort | neither loss of bik alone, nor combined loss of bik and noxa, accelerate murine lymphoma development or render lymphoma cells resistant to dna damaging drugs |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366076/ https://www.ncbi.nlm.nih.gov/pubmed/22573037 http://dx.doi.org/10.1038/cddis.2012.42 |
work_keys_str_mv | AT happol neitherlossofbikalonenorcombinedlossofbikandnoxaacceleratemurinelymphomadevelopmentorrenderlymphomacellsresistanttodnadamagingdrugs AT phipsonb neitherlossofbikalonenorcombinedlossofbikandnoxaacceleratemurinelymphomadevelopmentorrenderlymphomacellsresistanttodnadamagingdrugs AT smythgk neitherlossofbikalonenorcombinedlossofbikandnoxaacceleratemurinelymphomadevelopmentorrenderlymphomacellsresistanttodnadamagingdrugs AT strassera neitherlossofbikalonenorcombinedlossofbikandnoxaacceleratemurinelymphomadevelopmentorrenderlymphomacellsresistanttodnadamagingdrugs AT scottcl neitherlossofbikalonenorcombinedlossofbikandnoxaacceleratemurinelymphomadevelopmentorrenderlymphomacellsresistanttodnadamagingdrugs |